What are the newest treatments for Ovarian Cancer in 2026

Newest Ovarian Cancer Treatments in 2026

Based on the most current NCCN Guidelines (Version 3.2025), here are the cutting-edge treatment approaches for ovarian cancer:

1. PARP Inhibitors (Poly ADP-Ribose Polymerase Inhibitors)

These are among the most important advances for ovarian cancer patients. PARP inhibitors work by blocking a protein that helps cancer cells repair DNA damage, making them more vulnerable to treatment.

Current FDA-approved PARP inhibitors include:

• Olaparib - for patients with BRCA1/2 mutations
• Rucaparib - for BRCA-mutated disease
• Niraparib - for platinum-sensitive recurrent disease

According to NCCN Guidelines, these are now used as maintenance therapy (ongoing treatment after chemotherapy) for patients with:

• Newly diagnosed advanced ovarian cancer with BRCA mutations
• Platinum-sensitive recurrent disease (cancer that responds to platinum-based chemotherapy)

Key point: If you have a BRCA mutation, ask your doctor about PARP inhibitor maintenance therapy—research shows these can significantly extend the time before cancer returns.

---

2. Bevacizumab (Anti-Angiogenesis Therapy)

Bevacizumab works by cutting off the blood supply that tumors need to grow. According to NCCN Guidelines, it's now used in combination with:

• Chemotherapy for platinum-resistant recurrent ovarian cancer
• Maintenance therapy after chemotherapy response
• Combined with PARP inhibitors in certain situations

Important note: NCCN Guidelines recommend discontinuing bevacizumab before starting PARP inhibitor maintenance therapy.

---

3. Folate Receptor Alpha (FRα)-Targeting Therapy

Mirvetuximab soravtansine is a newer antibody-drug conjugate (a targeted therapy that delivers chemotherapy directly to cancer cells) that targets folate receptor alpha.

According to NCCN Guidelines, this is used for:

• Platinum-resistant ovarian cancer with high FRα expression
• Can be combined with bevacizumab for enhanced effectiveness

This represents a significant advance because it targets a specific protein on ovarian cancer cells, potentially causing fewer side effects than traditional chemotherapy.

---

4. Combination Approaches

The newest treatment strategies combine multiple therapies:

For Platinum-Sensitive Recurrent Disease:

• Platinum-based chemotherapy + bevacizumab (preferred for first recurrence)
• PARP inhibitor maintenance (if BRCA-mutated or HRD-positive)
• Bevacizumab continuation as maintenance

For Platinum-Resistant Disease:

• Non-platinum chemotherapy options (gemcitabine, pegylated liposomal doxorubicin, paclitaxel)
• Bevacizumab-containing regimens
• Mirvetuximab soravtansine (especially for FRα-positive tumors)
• Immunotherapy combinations (pembrolizumab with bevacizumab and metronomic cyclophosphamide)

---

5. Molecular Testing (Critical for Treatment Selection)

According to NCCN Guidelines, validated molecular testing should be performed to identify which targeted therapies might work best. Testing should include:

• BRCA1/2 status (germline and somatic)
• HRD (Homologous Recombination Deficiency) status
• FRα (Folate Receptor Alpha) expression
• MSI/MMR (mismatch repair status)
• TMB (tumor mutational burden)
• BRAF, RET, NTRK mutations

Why this matters: These tests help your doctor choose the most effective targeted therapy for YOUR specific cancer, rather than using a one-size-fits-all approach.

---

6. Immunotherapy Combinations

Emerging research shows promise with:

• Pembrolizumab (checkpoint inhibitor) combined with bevacizumab and oral metronomic cyclophosphamide for recurrent ovarian cancer
• These combinations are being studied in clinical trials

---

Questions to Ask Your Oncologist:

1. "Has my tumor been tested for BRCA mutations and HRD status?" (This determines if PARP inhibitors are an option)

2. "What is my folate receptor alpha (FRα) expression level?" (This determines if mirvetuximab soravtansine might be appropriate)

3. "Am I a candidate for maintenance therapy after chemotherapy?" (PARP inhibitors or bevacizumab can extend remission)

4. "If my cancer becomes platinum-resistant, what are my treatment options?" (Mirvetuximab, bevacizumab combinations, or immunotherapy)

5. "Are there clinical trials available for my specific cancer profile?" (Newer combinations are constantly being tested)

6. "What is my platinum sensitivity status?" (This guides whether platinum-based chemotherapy is still an option)

---

Important Context:

According to NCCN Guidelines, treatment decisions should be individualized based on:

• Your specific cancer type and stage
• Molecular testing results
• Prior treatments received
• Your overall health and tolerance for side effects
• Your personal preferences

The field of ovarian cancer treatment is rapidly evolving. What's considered standard care in 2026 reflects major advances in understanding how to target specific vulnerabilities in ovarian cancer cells.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.